Table 1.
Baseline renal function–related clinical characteristics of patients from FOS and Schiffmann et al. [21] who were included in the analyses of the progression of renal impairment.
| By baseline eGFR (mL/min/1.73 m2) |
||||||||
|---|---|---|---|---|---|---|---|---|
| Parameter (mean at baseline) | FOS Evaluable Treated Renal cohort |
Schiffmann et al. (untreated) [21] |
||||||
| Males (n = 135) |
Females (n = 133) |
Males (n = 243) |
Females (n = 152) |
|||||
| ≥ 60 (n = 117) | < 60 (n = 18) | ≥ 60 (n = 111) | < 60 (n = 22) | ≥ 60 (n = 189) | < 60 (n = 54) | ≥ 60 (n = 129) | < 60 (n = 23) | |
| Age (yrs) | 34.7 | 44.1 | 44.1 | 55.8 | 27.3 | 41.8 | 38.0 | 51.9 |
| Urinary protein (g/24 h) | 0.4 | 1.5 | 0.5 | 1.0 | 0.6 | 2.6 | 0.3 | 1.1 |
| Overt proteinuria (%) | 40 | 93 | 37 | 56 | 37 | 96 | 20 | 50 |
| Systolic BP (mm Hg) | 124 | 124 | 126 | 133 | 125 | 128 | 123 | 135 |
| Diastolic BP (mm Hg) | 73 | 77 | 74 | 76 | 74 | 79 | 75 | 82 |
| By baseline urinary protein (g/24 h) |
||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Parameter (mean at baseline) | FOS Evaluable Treated Renal cohort |
Schiffmann et al. (untreated) [21] |
||||||||||
| Males (n = 105) |
Females (n = 109) |
Males (n = 61) |
Females (n = 29) |
|||||||||
| ≥ 1.0 (n = 16) | 0.1 to 1.0 (n = 74) | < 0.1 (n = 15) | ≥ 1.0 (n = 17) | 0.1 to 1.0 (n = 70) | < 0.1 (n = 22) | ≥ 1.0 (n = 22) | 0.1 to 1.0 (n = 21) | < 0.1 (n = 18) | ≥ 1.0 (n = 5) | 0.1 to 1.0 (n = 17) | < 0.1 (n = 7) | |
| Age (yrs) | 38.8 | 36.1 | 37.0 | 46.9 | 45.7 | 42.1 | 38.9 | 36.0 | 22.8 | 47.2 | 42.3 | 39.0 |
| eGFR (mL/min/1.73 m2) | 74.4 | 101.8 | 105.0 | 65.7 | 87.3 | 80.2 | 58.5 | 84.6 | 138.0 | 63.4 | 89.6 | 91.9 |
BP, blood pressure; eGFR, estimated glomerular filtration rate; FOS, Fabry Outcome Survey.